| Title |
Immunomodifiers in combination with conventional chemotherapy in small cell lung cancer: a Phase II, randomized study
|
|---|---|
| Published in |
Drug Design, Development and Therapy, July 2013
|
| DOI | 10.2147/dddt.s43184 |
| Pubmed ID | |
| Authors |
Konstantinos Zarogoulidis, Eftimios Ziogas, Efimia Boutsikou, Paul Zarogoulidis, Kaid Darwiche, Theodoros Kontakiotis, Kosmas Tsakiridis, Konstantinos Porpodis, Dimitrios Latsios, Olga Chatzizisi, Ilias Karapantzos, Qiang Li, Georgios Kyriazis |
| Abstract |
To evaluate the effect of immunotherapy on response, survival, and certain immune markers in patients with small cell lung cancer (SCLC) who are receiving chemotherapy. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 51 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 51 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 10 | 20% |
| Other | 6 | 12% |
| Student > Bachelor | 6 | 12% |
| Researcher | 6 | 12% |
| Student > Doctoral Student | 4 | 8% |
| Other | 10 | 20% |
| Unknown | 9 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 18 | 35% |
| Nursing and Health Professions | 6 | 12% |
| Biochemistry, Genetics and Molecular Biology | 4 | 8% |
| Agricultural and Biological Sciences | 3 | 6% |
| Chemical Engineering | 1 | 2% |
| Other | 5 | 10% |
| Unknown | 14 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 July 2013.
All research outputs
#22,759,802
of 25,374,647 outputs
Outputs from Drug Design, Development and Therapy
#1,754
of 2,268 outputs
Outputs of similar age
#183,614
of 206,711 outputs
Outputs of similar age from Drug Design, Development and Therapy
#31
of 39 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,268 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 206,711 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 39 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.